Browse AURKA

Summary
SymbolAURKA
Nameaurora kinase A
Aliases BTAK; AurA; ARK1; PPP1R47; AIK; protein phosphatase 1, regulatory subunit 47; Aurora-A kinase; STK15; STK6; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle pole Cytoplasm, cytoskeleton, cilium basal body Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Note=Detected at the neurite hillock in developing neurons (By similarity). Localizes at the centrosome in mitotic cells from early prophase until telophase, but also localizes to the spindle pole MTs from prophase to anaphase (PubMed:9606188, PubMed:17229885, PubMed:21225229). Colocalized with SIRT2 at centrosome (PubMed:22014574). Moves to the midbody during both telophase and cytokinesis (PubMed:17726514). Associates with both the pericentriolar material (PCM) and centrioles (PubMed:22014574).
Domain PF00069 Protein kinase domain
Function

Mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression. Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. Required for initial activation of CDK1 at centrosomes. Phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. Regulates KIF2A tubulin depolymerase activity. Required for normal axon formation. Plays a role in microtubule remodeling during neurite extension. Important for microtubule formation and/or stabilization. Also acts as a key regulatory component of the p53/TP53 pathway, and particularly the checkpoint-response pathways critical for oncogenic transformation of cells, by phosphorylating and stabilizing p53/TP53. Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) isoforms, to inhibit their activity. Necessary for proper cilia disassembly prior to mitosis.

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000077 DNA damage checkpoint
GO:0000082 G1/S transition of mitotic cell cycle
GO:0000086 G2/M transition of mitotic cell cycle
GO:0000212 meiotic spindle organization
GO:0000226 microtubule cytoskeleton organization
GO:0000910 cytokinesis
GO:0001556 oocyte maturation
GO:0003002 regionalization
GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest
GO:0007050 cell cycle arrest
GO:0007051 spindle organization
GO:0007052 mitotic spindle organization
GO:0007056 spindle assembly involved in female meiosis
GO:0007057 spindle assembly involved in female meiosis I
GO:0007067 mitotic nuclear division
GO:0007088 regulation of mitotic nuclear division
GO:0007093 mitotic cell cycle checkpoint
GO:0007098 centrosome cycle
GO:0007100 mitotic centrosome separation
GO:0007126 meiotic nuclear division
GO:0007127 meiosis I
GO:0007143 female meiotic division
GO:0007144 female meiosis I
GO:0007281 germ cell development
GO:0007292 female gamete generation
GO:0007346 regulation of mitotic cell cycle
GO:0007389 pattern specification process
GO:0009798 axis specification
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0009948 anterior/posterior axis specification
GO:0009952 anterior/posterior pattern specification
GO:0009994 oocyte differentiation
GO:0010498 proteasomal protein catabolic process
GO:0010720 positive regulation of cell development
GO:0010948 negative regulation of cell cycle process
GO:0016049 cell growth
GO:0016570 histone modification
GO:0016572 histone phosphorylation
GO:0018105 peptidyl-serine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0021700 developmental maturation
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0030330 DNA damage response, signal transduction by p53 class mediator
GO:0031023 microtubule organizing center organization
GO:0031145 anaphase-promoting complex-dependent catabolic process
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031570 DNA integrity checkpoint
GO:0031571 mitotic G1 DNA damage checkpoint
GO:0031647 regulation of protein stability
GO:0032091 negative regulation of protein binding
GO:0032434 regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0032436 positive regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0032465 regulation of cytokinesis
GO:0032886 regulation of microtubule-based process
GO:0035404 histone-serine phosphorylation
GO:0042176 regulation of protein catabolic process
GO:0042770 signal transduction in response to DNA damage
GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043393 regulation of protein binding
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0044380 protein localization to cytoskeleton
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044773 mitotic DNA damage checkpoint
GO:0044774 mitotic DNA integrity checkpoint
GO:0044783 G1 DNA damage checkpoint
GO:0044819 mitotic G1/S transition checkpoint
GO:0044839 cell cycle G2/M phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045732 positive regulation of protein catabolic process
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045840 positive regulation of mitotic nuclear division
GO:0045862 positive regulation of proteolysis
GO:0045930 negative regulation of mitotic cell cycle
GO:0045931 positive regulation of mitotic cell cycle
GO:0046605 regulation of centrosome cycle
GO:0046777 protein autophosphorylation
GO:0048469 cell maturation
GO:0048477 oogenesis
GO:0048588 developmental cell growth
GO:0048599 oocyte development
GO:0051098 regulation of binding
GO:0051100 negative regulation of binding
GO:0051225 spindle assembly
GO:0051297 centrosome organization
GO:0051299 centrosome separation
GO:0051302 regulation of cell division
GO:0051321 meiotic cell cycle
GO:0051493 regulation of cytoskeleton organization
GO:0051640 organelle localization
GO:0051642 centrosome localization
GO:0051783 regulation of nuclear division
GO:0051785 positive regulation of nuclear division
GO:0060281 regulation of oocyte development
GO:0060282 positive regulation of oocyte development
GO:0060560 developmental growth involved in morphogenesis
GO:0061136 regulation of proteasomal protein catabolic process
GO:0070507 regulation of microtubule cytoskeleton organization
GO:0071156 regulation of cell cycle arrest
GO:0071158 positive regulation of cell cycle arrest
GO:0071539 protein localization to centrosome
GO:0072331 signal transduction by p53 class mediator
GO:0072395 signal transduction involved in cell cycle checkpoint
GO:0072401 signal transduction involved in DNA integrity checkpoint
GO:0072413 signal transduction involved in mitotic cell cycle checkpoint
GO:0072422 signal transduction involved in DNA damage checkpoint
GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint
GO:0072698 protein localization to microtubule cytoskeleton
GO:0090068 positive regulation of cell cycle process
GO:0090306 spindle assembly involved in meiosis
GO:1900193 regulation of oocyte maturation
GO:1900195 positive regulation of oocyte maturation
GO:1901796 regulation of signal transduction by p53 class mediator
GO:1901800 positive regulation of proteasomal protein catabolic process
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint
GO:1902402 signal transduction involved in mitotic DNA damage checkpoint
GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:1903046 meiotic cell cycle process
GO:1903050 regulation of proteolysis involved in cellular protein catabolic process
GO:1903052 positive regulation of proteolysis involved in cellular protein catabolic process
GO:1903362 regulation of cellular protein catabolic process
GO:1903364 positive regulation of cellular protein catabolic process
GO:1903429 regulation of cell maturation
GO:1903431 positive regulation of cell maturation
GO:1990138 neuron projection extension
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
GO:2000241 regulation of reproductive process
GO:2000243 positive regulation of reproductive process
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004712 protein serine/threonine/tyrosine kinase activity
GO:0031625 ubiquitin protein ligase binding
GO:0035173 histone kinase activity
GO:0035174 histone serine kinase activity
GO:0044389 ubiquitin-like protein ligase binding
Cellular Component GO:0000775 chromosome, centromeric region
GO:0000779 condensed chromosome, centromeric region
GO:0000780 condensed nuclear chromosome, centromeric region
GO:0000793 condensed chromosome
GO:0000794 condensed nuclear chromosome
GO:0000922 spindle pole
GO:0001674 female germ cell nucleus
GO:0005813 centrosome
GO:0005814 centriole
GO:0005819 spindle
GO:0005874 microtubule
GO:0005875 microtubule associated complex
GO:0005876 spindle microtubule
GO:0005929 cilium
GO:0030424 axon
GO:0030496 midbody
GO:0031616 spindle pole centrosome
GO:0032133 chromosome passenger complex
GO:0033267 axon part
GO:0042585 germinal vesicle
GO:0043025 neuronal cell body
GO:0043073 germ cell nucleus
GO:0043203 axon hillock
GO:0044297 cell body
GO:0044450 microtubule organizing center part
GO:0044454 nuclear chromosome part
GO:0045120 pronucleus
GO:0051233 spindle midzone
GO:0072686 mitotic spindle
GO:0072687 meiotic spindle
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG hsa04114 Oocyte meiosis
Reactome R-HSA-174143: APC/C-mediated degradation of cell cycle proteins
R-HSA-174178: APC/C
R-HSA-8854518: AURKA Activation by TPX2
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-8854050: FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
R-HSA-69275: G2/M Transition
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-8854521: Interaction between PHLDA1 and AURKA
R-HSA-392499: Metabolism of proteins
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-597592: Post-translational protein modification
R-HSA-2565942: Regulation of PLK1 Activity at G2/M Transition
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation
R-HSA-453276: Regulation of mitotic cell cycle
R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins
R-HSA-2990846: SUMOylation
R-HSA-4615885: SUMOylation of DNA replication proteins
R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes
R-HSA-6804114: TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolAURKA
Nameaurora kinase A
Aliases BTAK; AurA; ARK1; PPP1R47; AIK; protein phosphatase 1, regulatory subunit 47; Aurora-A kinase; STK15; STK6; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AURKA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between AURKA and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26719346MelanomaInhibit immunity (infiltration)AURKAi and CDK4/6i promoted the recruitment of TILs by inducing CCL5 secretion in melanoma cells (P ≤ .005) in an NF-κB-dependent manner.
25398437MelanomaInhibit immunityHere we show how combining a senescence-inducing inhibitor of the mitotic kinase Aurora A (AURKA) with an MDM2 antagonist activates p53 in senescent tumors harboring wildtype 53. In the model studied, this effect is accompanied proliferation arrest, mitochondrial depolarization, apoptosis and immune clearance of cancer cells by antitumor leukocytes in a manner reliant upon CCL5, CCL1 and CXCL9.
22025529LeukemiaImmunotherapy targetAurora kinase A (AURKA) is overexpressed in leukemias. Previously, we demonstrated that AURKA-specific CD8(+) T cells specifically and selectively lysed leukemia cells, indicating that AURKA is an excellent target for immunotherapy. Furthermore, TCR-redirected CD8(+) T cells lysed AURKA-overexpressing human leukemic cells in an HLA-A*0201-restricted manner, but did not kill HLA-A*0201(+) normal cells, including hematopoietic progenitors.
18820130LeukemiaImmunotherapy targetAurora-A kinase: a novel target of cellular immunotherapy for leukemia. Aur-A-specific CTLs were able to lyse human leukemia cell lines and freshly isolated leukemia cells, but not normal cells, in an HLA-A*0201-restricted manner.
Summary
SymbolAURKA
Nameaurora kinase A
Aliases BTAK; AurA; ARK1; PPP1R47; AIK; protein phosphatase 1, regulatory subunit 47; Aurora-A kinase; STK15; STK6; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AURKA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.86 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolAURKA
Nameaurora kinase A
Aliases BTAK; AurA; ARK1; PPP1R47; AIK; protein phosphatase 1, regulatory subunit 47; Aurora-A kinase; STK15; STK6; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AURKA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4530.164
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0730.966
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.740.599
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0780.88
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0040.997
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1720.921
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0760.855
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2090.886
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5480.698
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0450.967
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2040.899
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.410.000798
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AURKA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAURKA
Nameaurora kinase A
Aliases BTAK; AurA; ARK1; PPP1R47; AIK; protein phosphatase 1, regulatory subunit 47; Aurora-A kinase; STK15; STK6; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AURKA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAURKA
Nameaurora kinase A
Aliases BTAK; AurA; ARK1; PPP1R47; AIK; protein phosphatase 1, regulatory subunit 47; Aurora-A kinase; STK15; STK6; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AURKA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AURKA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAURKA
Nameaurora kinase A
Aliases BTAK; AurA; ARK1; PPP1R47; AIK; protein phosphatase 1, regulatory subunit 47; Aurora-A kinase; STK15; STK6; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AURKA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAURKA
Nameaurora kinase A
Aliases BTAK; AurA; ARK1; PPP1R47; AIK; protein phosphatase 1, regulatory subunit 47; Aurora-A kinase; STK15; STK6; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AURKA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAURKA
Nameaurora kinase A
Aliases BTAK; AurA; ARK1; PPP1R47; AIK; protein phosphatase 1, regulatory subunit 47; Aurora-A kinase; STK15; STK6; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AURKA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAURKA
Nameaurora kinase A
Aliases BTAK; AurA; ARK1; PPP1R47; AIK; protein phosphatase 1, regulatory subunit 47; Aurora-A kinase; STK15; STK6; ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AURKA collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting AURKA.
ID Name Drug Type Targets #Targets
DB02482PhosphonothreonineSmall MoleculeAURKA, CDK7, MAPK1, MAPK12, PRKACA, PRKACB, PRKCQ, RHO, S100A119
DB05169AT9283Small MoleculeAURKA, AURKB2
DB05198CYC116Small MoleculeAURKA, KDR2
DB05220AlisertibSmall MoleculeAURKA1
DB06134SNS-314Small MoleculeAURKA, AURKC2
DB06486EnzastaurinSmall MoleculeAKT1, AURKA, AURKB, CDK15, CHEK1, CHEK2, PIK3R1, PRKCB8
DB071864-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDESmall MoleculeAURKA, PLK12
DB072668-ethyl-3,10,10-trimethyl-4,5,6,8,10,12-hexahydropyrazolo[4',3':6,7]cyclohepta[1,2-b]pyrrolo[2,3-f]indol-9(1H)-oneSmall MoleculeAURKA1
DB073601-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]ureaSmall MoleculeAURKA1
DB073621-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]ureaSmall MoleculeAURKA1
DB07545N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDESmall MoleculeAURKA1
DB07801N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamideSmall MoleculeAURKA1
DB080652-(1H-pyrazol-3-yl)-1H-benzimidazoleSmall MoleculeAURKA1
DB08066N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDESmall MoleculeAURKA, CDK22
DB13061MLN8054Small MoleculeAURKA1